tirzepatide non responders How Does Support Weight Management? GLP-1 medication and nonresponders: why

REIMAGINE 1 evaluated CagriSema as monotherapy for individuals living with type 2 diabetes who are drug-nave and have not responded adequately to lifestyle therapy

The Study Researchers pulled a 10 percent random sample from the Australian Pharmaceutical Benefits Scheme (PBS) that included data from over 1.7 million individuals over the ten year period, from 2012 to 2022

Adding to the mounting reasons why HCPs choose Wegovy , the FDA expanded the label in 2024 to include an indication for reduction of the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight

Among males ( n = 2,998,317), treatment was associated with 58,098 fewer MACE (~ 15% relative reduction), 14,956 fewer cardiovascular deaths (~ 7%), 43,931 fewer nonfatal myocardial infarctions (~ 25%), and 12,884 fewer nonfatal strokes (~ 12%)

Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden

Researchers intending to work with the lyophilised version should ensure access to DMSO or a similar solvent for proper handling